^
Association details:
| Biomarker: | CREBBP mutation |
|---|---|
| Cancer: | Bladder Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1774P - Association of CREBBP mutation with favorable outcome with immune checkpoint inhibitors in bladder cancer
Published date:
09/05/2022
Excerpt:
The Cox proportional-hazards regression demonstrated that CREBBP mutation was significantly associated with better OS (HR [95%CI]: 0.43[0.20-0.92], P=0.030)...CREBBP mutation shows a favorable link between CREBBP mutation with efficacy of ICIs.
Source:
Title:
Abstract 5102: Correlation analysis of CREBBP mutation with tumor mutation burden and effect of immune checkpoint therapy in bladder cancer
Published date:
06/15/2022
Excerpt:
While in MSKCC ICIs treatment cohort, the overall survival (OS) of CREBBP mutation group (n=26) were significantly longer than wild-type group (n=166) (median OS, mutation vs wild-type = NE vs 15 months; HR 0.468 [95% CI 0.26-0.84]; P = 0.0431)....Clinical cohort analysis results suggested that CREBBP might be a predictive biomarker of immune checkpoint therapy but not a prognostic factor in BLCA.
DOI:
10.1158/1538-7445.AM2022-5102
Source:
Title:
Investigation of CREBBP mutation and correlation with immunotherapy biomarker in Chinese bladder cancer patients.
Published date:
05/26/2022
Excerpt:
An independent cohorts (the MSKCC study cohort) with next generation sequencing (NGS) data from 211 patients with bladder cancer of pan-cancer, which were used to analyze the prognostic effect of CREBBP on immunotherapy....there was significant difference on overall survival (OS) (HR = 0.43; 95% CI, 0.21–0.90; P = 0.02) between CREBBPmut (median, 12 months) and CREBBPwt (median, 8 months).
DOI:
10.1200/JCO.2022.40.16_suppl.e16537
